Opinion|Videos|February 6, 2025
Shifting Treatment Paradigms in R/R ALL
Panelists discuss how minimal residual disease (MRD) outcomes with obecabtagene autoleucel (obe-cel) compare with those with brexucabtagene autoleucel (brexu-cel) and how the FDA approval of obe-cel may impact treatment decisions in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), including considerations for patient factors, such as MRD status, Philadelphia status, and high-risk features.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Shaughnessy: What are your impressions of the MRD outcomes with obe-cel compared with MRD outcomes reported with brexu-cel so far?
- Resource links:
Valtis YK et al. MRD negativity D28 after brexu-cel. ASH 2024 abstract, or see Appendix 5. - Dr. O’Dwyer to Dr. Logan [then open to panelists]: How does the FDA approval of obe-cel change your treatment landscape and decisions for R/R ALL?
- Are there specific patients with R/R ALL for whom you would more likely consider brexu-cel vs obe-cel [eg, Philadelphia status, MRD status, high-risk features, extramedullary disease, age, performance score]?
- Does the FDA approval without a Risk Evaluation Mitigation Strategy program influence your treatment approach?
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5